Clinical Trial Update: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

This four-year extension trial reports long-term efficacy and safety of secukinumab in adults with chronic plaque psoriasis. The Phase 3 study results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Chronic Plaque-Type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-05-25